isoflavones / Casp3 Cancer Research Results

isoFl, isoflavones: Click to Expand ⟱
Features:
Isoflavones occur in many plant species, but are especially high in soybeans.
Major isoflavones in soybean are genistein and daidzein
Supplementation may help lower the risk of hormone-related cancers.

Isoflavones — plant-derived polyphenolic compounds belonging to the flavonoid family and functioning as phytoestrogens with selective estrogen receptor modulator-like activity. The principal dietary soy isoflavones are genistein, daidzein, and glycitein, occurring largely as the glycosides genistin, daidzin, and glycitin before intestinal hydrolysis. Common abbreviations include IFs, soy isoflavones, and SIFs. Soybeans and soy foods are the major human dietary sources, while red clover and other legumes contain additional isoflavones such as biochanin A and formononetin. Genistein is substantially more mechanistically characterized than other members of the class, so many anticancer effects attributed broadly to isoflavones are principally supported by genistein studies. Isoflavones preferentially activate ERβ at physiologically relevant concentrations but can activate ERα as exposure increases, making biological effects strongly dependent on dose, tissue, estrogen-receptor composition, metabolism, and individual equol-producing status.

Primary mechanisms (ranked):

  1. Selective estrogen receptor modulation with preferential ERβ agonism at lower concentrations and increasingly mixed ERβ/ERα activity at higher concentrations.
  2. Suppression of proliferative survival signaling including PI3K/Akt/mTOR, NF-κB, JAK/STAT, MAPK/ERK, and Wnt/β-catenin pathways, particularly for genistein.
  3. Induction of cell-cycle arrest and mitochondrial apoptosis through Bcl-2 family modulation, caspase activation, and loss of mitochondrial membrane potential.
  4. Suppression of epithelial-mesenchymal transition, cancer stem-cell phenotypes, migration, invasion, and metastatic signaling.
  5. Antiangiogenic activity and inhibition of tumor-associated growth signaling.
  6. Epigenetic modulation, including altered DNA methylation and re-expression of tumor-suppressive pathways such as ERβ in some prostate-cancer models.
  7. ROS modulation is secondary and strongly concentration- and model-dependent: antioxidant activity can occur at physiological exposure, whereas high experimental concentrations of genistein can increase mitochondrial ROS and promote apoptosis.

Bioavailability / PK relevance: Orally administered isoflavone glycosides are hydrolyzed in the intestine and absorbed as aglycones, followed by extensive glucuronidation and sulfation. Circulating genistein and daidzein therefore consist predominantly of conjugated metabolites, with only a small fraction present as unconjugated biologically active aglycone. Genistein generally produces greater systemic exposure than daidzein. Daidzein may be converted by intestinal microbiota to equol, but only a subset of individuals consistently produce substantial equol, creating marked interindividual variability. Food matrix, intestinal transit, microbiome composition, glycoside form, and formulation materially affect exposure.

In-vitro vs systemic exposure relevance: A major translational limitation exists. Many direct anticancer experiments use approximately 25–100 µM genistein, with some cytotoxic IC50 values exceeding 100 µM, whereas unconjugated genistein after ordinary dietary or supplemental exposure is generally far below these concentrations and represents only a small fraction of circulating total isoflavones. ERβ-mediated signaling and other high-affinity endocrine effects can occur at substantially lower concentrations and are therefore more pharmacologically plausible in humans than many high-concentration kinase inhibition, ROS, or direct cytotoxicity findings.

Clinical evidence status: Human evidence is substantial for dietary exposure and supplement safety but limited for treatment of established cancer. Small randomized trials in prostate cancer demonstrate changes in tumor-associated molecular biomarkers, but convincing reductions in tumor progression, recurrence, or cancer mortality have not been established in therapeutic RCTs. Observational studies associate soy/isoflavone intake with lower incidence or recurrence of some hormone-related cancers, including breast cancer, but these data do not establish treatment efficacy. Isoflavones are therefore best classified as dietary/chemopreventive candidates with human biomarker and observational evidence rather than established anticancer drugs or standard adjunctive cancer therapy.

Cancer-Relevant Isoflavone Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 Estrogen receptor signaling ERβ ↑; ERα variable ↑ (dose-dependent) ERβ ↑; ERα variable ↑ Tissue-selective estrogen signaling Genistein and daidzein preferentially activate ERβ at lower concentrations. At higher concentrations ERα activation becomes more important, making tumor ERα/ERβ balance a major determinant of response.
2 PI3K Akt mTOR survival signaling ↓ ↔ or ↓ (context-dependent) Reduced proliferation and survival Best supported for genistein. Often linked to reduced Akt phosphorylation and downstream mitochondrial apoptosis.
3 Mitochondrial apoptosis ↑ ↔ (context-dependent) Programmed cell death Bax/Bcl-2 balance shifts toward apoptosis, mitochondrial membrane potential decreases, and cytochrome-dependent caspase pathways may become activated.
4 Caspase cascade Caspase-3 ↑; Caspase-7 ↑ ↔ Execution of apoptosis Observed in multiple genistein and daidzein cancer models but commonly at concentrations above typical free systemic exposure.
5 Bcl-2 family balance Bcl-2 ↓; Bax ↑ ↔ or mixed Lower apoptotic threshold Contributes to mitochondrial permeabilization and downstream caspase activation.
6 Wnt β-catenin signaling ↓ ↔ or ↓ (context-dependent) Reduced stemness, proliferation, and invasion Particularly relevant to experimental cancer stem-cell and EMT models.
7 Epithelial mesenchymal transition ↓ ↔ Reduced invasion and metastatic phenotype Genistein can suppress EMT-associated transcriptional programs including Snail, Slug, ZEB-related, and β-catenin signaling in model-dependent systems.
8 Cancer stem-cell phenotype ↓ Not established Reduced self-renewal and tumor-initiating characteristics Reported effects include reductions in stemness-associated phenotypes and markers, but evidence is primarily preclinical.
9 NF-κB inflammatory survival signaling ↓ ↓ (context-dependent) Reduced inflammatory and anti-apoptotic signaling One component of the pleiotropic signaling effects particularly associated with genistein.
10 JAK STAT signaling ↓ (model-dependent) ↔ or ↓ Reduced proliferation and survival signaling Evidence varies substantially by tumor model and individual isoflavone.
11 MAPK ERK signaling ↓ or mixed (context-dependent) Mixed Altered proliferation and stress signaling Direction varies with receptor status, dose, cell type, and duration of exposure.
12 Cell-cycle regulation CDK activity ↓; cell-cycle arrest ↑ ↔ or ↓ proliferation Suppression of cellular proliferation Genistein can produce G1/S or G2/M arrest depending on tumor model and concentration.
13 Angiogenesis ↓ ↔ or ↓ (context-dependent) Reduced tumor vascular support Primarily supported by preclinical genistein studies.
14 Epigenetic regulation Aberrant methylation ↓ (model-dependent) Mixed Re-expression of tumor-suppressive programs Physiologically relevant genistein concentrations have reduced ERβ promoter methylation and increased ERβ expression in some prostate-cancer models.
15 Mitochondrial ROS increase ROS ↑ (high concentration only) ROS ↓ or ↔ (context-dependent) Oxidative stress-mediated apoptosis Secondary mechanism. Pro-oxidant effects commonly require tens to hundreds of micromolar genistein, while lower exposures may instead be antioxidant.
16 Chemosensitization ↑ (model-dependent) Not established Potential enhancement of anticancer-drug response Synergy with several chemotherapeutic agents has been reported preclinically, but this is not an established clinical adjunct indication.
17 Clinical Translation Constraint High-concentration mechanisms often not systemically achievable Extensive conjugation limits free aglycone exposure Limits translation of direct cytotoxic mechanisms Free circulating genistein is only a small fraction of total plasma genistein. Many experimental anticancer effects occur at 25–100 µM or higher, substantially exceeding typical unconjugated systemic concentrations. Composition of supplements and equol-producing status add further heterogeneity.


Alzheimer’s disease relevance: Soy isoflavones have plausible neurological mechanisms through ERβ signaling, antioxidant and anti-inflammatory effects, vascular effects, and metabolism of daidzein to equol. However, direct clinical evidence does not support isoflavones as an established Alzheimer treatment. In a randomized trial of patients with Alzheimer’s disease, 100 mg/day soy isoflavones for six months produced no significant overall cognitive benefit versus placebo. Exploratory associations between higher equol exposure and selected cognitive measures suggest that microbiome-dependent metabolism may modify response, but this remains unconfirmed.

Alzheimer-Relevant Isoflavone Effects

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Estrogen receptor beta signaling ↑ Neuroendocrine and neuronal signaling Mechanistically plausible because genistein and daidzein preferentially activate ERβ, which is expressed in brain regions involved in cognition.
2 Oxidative stress ↓ (context-dependent) Potential neuronal protection Predominantly preclinical evidence; effects depend on concentration and individual isoflavone.
3 Neuroinflammatory signaling ↓ (context-dependent) Potential reduction in inflammatory injury Primarily mechanistic and preclinical evidence.
4 Equol production ↑ biological activity in equol producers Possible modification of cognitive response Daidzein-to-equol conversion depends on intestinal microbiota and occurs only in a subset of individuals.
5 Clinical cognition ↔ No established cognitive improvement in Alzheimer’s disease A six-month randomized trial using 100 mg/day soy isoflavones found no significant cognitive benefit versus placebo.


Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
60- QC,  EGCG,  isoFl,    The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition
- in-vitro, Pca, pCSCs
Casp3↑, Casp7↑, Bcl-2↓, survivin↓, XIAP↓, EMT↓, Slug↓, Snail↓, β-catenin/ZEB1↓, LEF1↓, CSCs↓, Apoptosis↑, TumCMig↓, TumCI↓, CD44↓, CD133↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

XIAP↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp7↑, 1,   survivin↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 1,   CD44↓, 1,   CSCs↓, 1,   EMT↓, 1,  

Migration(tgid=13) ⓘ

LEF1↓, 1,   Slug↓, 1,   Snail↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   β-catenin/ZEB1↓, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:184  Target#:42  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page